Early and late morbidity of local excision after chemoradiotherapy for rectal cancer

B Teste, P Rouanet, J-J Tuech, A Valverde, B Lelong, M Rivoire, J-L Faucheron, M Jafari, G Portier, B Meunier, I Sielezneff, M Prudhomme, F Marchal, A Dubois, M Capdepont, Q Denost, E Rullier, B Teste, P Rouanet, J-J Tuech, A Valverde, B Lelong, M Rivoire, J-L Faucheron, M Jafari, G Portier, B Meunier, I Sielezneff, M Prudhomme, F Marchal, A Dubois, M Capdepont, Q Denost, E Rullier

Abstract

Background: Local excision (LE) after chemoradiotherapy is a new option in low rectal cancer, but morbidity has never been compared prospectively with total mesorectal excision (TME). Early and late morbidity were compared in patients treated either by LE or TME after neoadjuvant chemoradiotherapy for rectal cancer.

Method: This was a post-hoc analysis from a randomized trial. Patients with clinical T2/T3 low rectal cancer with good response to the chemoradiotherapy and having either LE, LE with eventual completion TME, or TME were considered. Early (1 month) and late (2 years) morbidities were compared between the three groups.

Results: There were no deaths following surgery in any of the three groups. Early surgical morbidity (20 per cent LE versus 36 per cent TME versus 43 per cent completion TME, P = 0.025) and late surgical morbidity (4 per cent versus 33 per cent versus 57 per cent, P < 0.001) were significantly lower in the LE group than in the TME or the completion TME group. of LE, was associated with the lowest rate of early (10 versus 18 versus 21 per cent, P = 0.217) and late medical morbidities (0 versus 7 versus 7 per cent, P = 0.154), although this did not represent a significant difference between the groups. The severity of overall morbidity was significantly lower at 2 years after LE compared with TME or completion TME (4 versus 28 versus 43 per cent grade 3-5, P < 0.001).

Conclusion: The rate of surgical complications after neoadjuvant chemoradiotherapy in the LE group was half that of TME group at 1 month and 10 times lower at 2 years. LE is a safe approach for organ preservation and should be considered as an alternative to watch-and-wait in complete clinical responders and to TME in subcomplete responders.

Trial registration: ClinicalTrials.gov NCT00427375.

© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.

Figures

Fig. 1
Fig. 1
Rate of complications following local excision and total mesorectal excision after neoadjuvant therapy Early surgical morbidity, P = 0.025; late surgical morbidity P < 0.001; early medical morbidity, P = 0.217; late medical morbidity, P = 0.154. LE, local excision; TME, total mesorectal excision; cTME, completion total mesorectal excision
Fig. 2
Fig. 2
Delay of occurrence of complications in the local excision and total mesorectal excision groups LE, local excision; TME, total mesorectal excision; cTME, completion total mesorectal excision

References

    1. Lezoche E, Baldarelli M, Lezoche G, Paganini AM, Gesuita R, Guerrieri M. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg 2012;99:1211–1218
    1. Pucciarelli S, De Paoli A, Guerrieri M, La Torre G, Maretto I, De Marchi F et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum 2013;56:1349–1356
    1. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015;16:1537–1546
    1. Smart CJ, Korsgen S, Hill J, Speake D, Levy B, Steward M et al. Multicentre study of short-course radiotherapy and transanal endoscopic microsurgery for early rectal cancer. Br J Surg 2016;103:1069–1075
    1. Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E et al.; for the CARTS Study Group. Long-term oncologic and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer, The CARTS study. JAMA Surg 2019;154:47–54
    1. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long term results. Ann Surg 2004;240:711–718
    1. Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016;17:174–183
    1. Martens MH, Maas M, Heijnen LA, Lambregts DMJ, Leijtens JWA, Stassen LPS et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst 2016;108:djw171.
    1. Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol 2019;5:e185896.
    1. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL et al.; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicenter registry study. Lancet 2018;391:2537–2545
    1. You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A national cohort study from the national cancer database. Ann Surg 2007;245:726–733
    1. Folkesson J, Johansson R, Påhlman L, Gunnarsson U. Population-based study of local surgery for rectal cancer. Br J Surg 2007;94:1421–1426
    1. Lee L, Burke JP, deBeche-Adams T, Nassif G, Martin-Perez B, Monson JRT et al. Transanal minimally invasive surgery for local excision of benign and malignant rectal neoplasia. Outcomes from 200 consecutive cases with midterm follow up. Ann Surg 2018;267:910–916
    1. Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech J-J, Valverde A et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol 2020;5:465–474
    1. Edge SB, Byrd DR, Carducci MA, Compton CC (eds). AJCC Cancer Staging Manual (7th edn). New York: Springer, 2009
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213
    1. Rullier E, Rouanet P, Tuech J-J, Valverde A, Lelong B, Rivoire M et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet 2017;390:469–479
    1. van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013;14:210–218
    1. Hallam S, Messenger DE, Thomas MG. A systematic review of local excision after neoadjuvant therapy for rectal cancer: are ypT0 tumors the limit? Dis Colon Rectum 2016;59:984–997
    1. Verseveld M, de Graaf EJR, Verhoef C, van Meerten E, Punt CJA, de Hingh IHJT et al.; CARTS Study Group. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 2015;102:853–860
    1. Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T et al. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94. Br J Surg 2018;105:1510–1518
    1. Lynn PB, Renfro LA, Carrero XW, Shi Q, Strombom PL, Chow O et al. Anorectal function and quality of life in patients with early rectal stage rectal cancer treated with chemoradiation and local excision. Dis Colon Rectum 2017;60:459–468
    1. Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2018;3:825–836

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe